Trials / Active Not Recruiting
Active Not RecruitingNCT06155136
RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan
Real-world Evidence on Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Long-term Survival After Treatment With Liposomal Irinotecan (NALLONG)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 163 (actual)
- Sponsor
- Servier Affaires Médicales · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to describe mPDAC patients still alive one year after the first cycle of nal-IRI
Detailed description
The objectives on patients still alive one year after the first cycle of nal-IRI : * Characterize mPDAC patient population according to their demographics * Identify PDAC treatment by line of treatment from diagnosis to last treatment * Explore prognostic factors of longer Overall Survival (OS) and Progression Free Survivor (PFS) among mPDAC patients showing long-term Survival
Conditions
Timeline
- Start date
- 2023-10-06
- Primary completion
- 2024-03-30
- Completion
- 2024-09-30
- First posted
- 2023-12-04
- Last updated
- 2024-04-22
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06155136. Inclusion in this directory is not an endorsement.